Our
Portfolio
Portfolio
Abcuro is a biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ABC008 toward the clinic, a first-in-class anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy muscle tissue in patients with inclusion body myositis (IBM). The company is also advancing ABC015, an anti-KLRG1 blocking antibody capable of reactivating inhibited cytotoxic T and NK cells in the tumor microenvironment.
AdvanCell is is advancing a first-in-isotope 212Pb PSMA targeting radioligand therapeutic for prostate cancer alongside a pipeline of radiotherapeutic programs supported by a leading 212Pb manufacturing capability.
Aetion is a health care technology company that delivers real-world evidence for life sciences, payers, providers, and regulator agencies.
Founded by Harvard Medical School faculty members with decades of experience in epidemiology and health outcomes research, Aetion informs health care’s most critical decisions — what works best, for whom, and when — to guide treatment development, commercialization, and payment innovation into health care’s modern era.
Aliada Therapeutics is a biotechnology company working to overcome delivery hurdles in CNS drug development. Aliada is advancing a new generation of CNS therapeutics using its novel BBB-crossing Modular Delivery (MODEL) platform technology, which has been shown to efficiently transport a diverse array of therapeutic cargoes into the brain, resulting in enhanced downstream effectiveness and addressing the critical need for efficient and versatile delivery technologies for large molecules and oligonucleotides. The company was co-founded by RA Capital Management, Raven, Johnson & Johnson, and Johnson & Johnson Innovation - JJDC, with further investment from OrbiMed and Sanofi Ventures.
Atalanta Therapeutics is developing a next-generation RNAi platform leveraging divalent small interfering RNA (di-siRNA) for selective gene silencing throughout the brain and spinal cord for diseases of the central nervous system.
Attovia is building a pipeline of biotherapeutics for the treatment of immune-mediated diseases. The company leverages ATTOBODY, its proprietary biologics platform, to generate first-in-class and best-in-class bispecifics and multispecifics with enhanced potency and tunable half-life.
Avilar Therapeutics is a biopharmaceutical company pioneering the discovery and development of extracellular protein degraders. Avilar develops ATACs (ASGPR Targeting Chimeras), a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded.
At the heart of bluebird bio's product creation efforts is its broadly applicable gene therapy platform for the development of novel treatments for diseases with few or no clinical options. The company's novel approach uses stem cells harvested from the patient's bone marrow into which a healthy version of the disease causing gene is inserted.
After being grown in culture, those cells are given back to the patient. bluebird bio's approach represents a true paradigm shift in the treatment of severe genetic diseases by eliminating the potential complications associated with donor cell transplantation and potentially presenting a one-time transformative therapy. Bluebird bio has two later stage clinical products in development for childhood cerebral adrenoleukodystrophy (CCALD) and beta-thalassemia/sickle cell anemia. The company is also applying its gene therapy platform to oncology through the development of chimeric antigen receptor T-cells in collaboration with Baylor University and Celgene.
Carbon Health is a modern health provider that is making high-quality healthcare more accessible to everyone. By combining advanced technology with expert care, they simplify access to a full spectrum of health needs – from acute issues to primary care, chronic conditions, as well as clinical research.
Carbon Health has built a full-stack technology platform that enables their patients to completely customize and optimize healthcare delivery to meet their needs. Their technology allows them to operate more efficiently than legacy health providers, effectively lowering the cost of care.
Carbon Health is removing traditional boundaries to make high-quality, transparent, and personal care accessible and affordable.
Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes. Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click’s lead prescription program is entering into a multi-center, randomized, controlled, parallel-group, phase III FDA registration trial for the treatment of Major Depressive Disorder in adults.
Common Sensing is introducing GoCap, a safer and more convenient way for diabetics to track and dose insulin. GoCap empowers patients by reducing the burden of manual logging, while providing helpful safety alerts and reminders. The aim is to connect patients, family, and care providers with better information feedback. By improving care engagement and motivation, GoCap holds the potential to improve quality of life for diabetics and reduce cost burdens for the health care system.
Curevo is a clinical stage company advancing a non-mRNA adjuvanted subunit vaccine for shingles with improved tolerability.
Curisium is a healthcare technology and services company that provides scalable innovative contracting solutions with its blockchain-based platform.
The Curisium platform uses cutting-edge blockchain and secure computation technologies to allow payers, providers, and life science companies to efficiently and securely engage in innovative, patient-centric value-based contracts.
By focusing on the in-vivo delivery of genetic cargoes to the microbiome, Eligo’s technology goes beyond traditional gene therapy and gene editing, expanding the range of addressable genetic targets. Through precise genetic modification within the human microbiome, this unique approach holds the promise of radically altering the course of numerous chronic and life-threatening diseases that are either triggered or driven by the expression of bacterial genes.
Empatica has developed a versatile smartwatch and sensor platform that allows for medical-grade continuous health monitoring.
Empatica's EmbracePlus wearable device is equipped with advanced sensors that allow for the remote collection of physiological data, giving researchers access to a vast range of raw sensor data and clinically validated digital biomarkers.
Their sophisticated full-stack research suite allows to seamlessly conduct clinical research in real-world settings, helping to develop new digital endpoints and digital biomarkers.
Escient Pharmaceuticals is a biotechnology company that is advancing first-in-class G Protein-Coupled Receptor (GPCR)-targeted drugs to address serious, unserved medical needs across a broad range of therapeutic indications. Focused on unleashing the therapeutic potential of specific orphan GPCRs, including the novel family of Mas-Related G-Protein Receptors (MRGPRs), Escient’s lead program targets MRGPRX4 for cholestatic and uremic pruritus. Based in San Diego, Calif., Escient is led by an experienced team of biotechnology entrepreneurs with specific expertise in GPCR drug discovery and development.
Rooted in rigorous science, Evidation captures and analyzes passive, continuous behavior data to quantify health outcomes that more accurately reflect an individual's day-to-day experience.
Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases. Based on exclusive worldwide rights to groundbreaking research from the laboratory of Matthew D. Disney, Ph.D., at The Scripps Research Institute, Expansion has assembled the intellectual property, know-how, and proprietary enabling technologies and tools necessary to facilitate the creation of potent and specific small molecule binders of RNA. Through this unique platform, Expansion is building a portfolio of novel RNA-targeted drug candidates with activity across a broad number of disease indications. The company’s initial development focus is on therapies for patients with expansion repeat diseases who currently have limited and unsatisfactory treatment options. Expansion is based in San Diego, California and Jupiter, Florida.
The Company’s first-in-class cell therapy products undergoing clinical development today utilize healthy donor cells, which are modified ex vivo using pharmacologic modulators, such as small molecules, to improve the cells’ biological properties and therapeutic function. The company is pioneering a revolutionary approach to cell therapy using renewable master induced pluripotent stem cell (iPSC) lines generated from a proprietary iPSC product platform to derive cell therapy products that can be delivered off-the-shelf for the treatment of a large number of patients. Fate Therapeutics is a public company headquartered in San Diego, CA, with a subsidiary in Ottawa, Canada.
Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients and their families by transforming gene regulation in disease. Fulcrum's therapies are based on modulating gene regulation via control of genetic on and off switches of disease genes. Fulcrum, headquartered in Cambridge, Mass., was launched by Third Rock Ventures in 2016 and named a "Fierce 15" company later that year.
GlycoMimetics is a public, clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Using its expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of glycomimetic drug candidates that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection.
"GlycoMimetics has enjoyed a very positive and productive relationship with SV. We have appreciated the opportunity to consult with functional area experts as well as to be in regular communication about the progress of our unpartnered programs. It’s great to have a chance to be ‘on the radar screen'."
Rachel K. King
CEO, GlycoMimetics
Glycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The company's approach is to use replacement therapies – substrates, enzymes, or proteins – and to target those molecules to clinically relevant cellular compartments. The company is based in San Carlos, California.
Chronic inflammatory diseases represent the most significant cause of death globally. Patients with autoimmune, inflammatory and fibrotic conditions are lacking efficacious treatment options. Granite Bio’s first-in-class assets are designed to target fundamental disease biology.
i2O Therapeutics is a biotechnology company developing safe and effective oral formulations of therapies traditionally limited to injections. Using an innovative ionic liquid technology, this platform leverages the benefits of protecting the drug cargo while also transiently enhancing permeation across the epithelial lining when administered orally. i2O is focused on creating the next generation of oral peptide and protein-based therapies.
Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. The company was founded on breakthrough computationally-designed virus like particle technology, exclusively licensed for a variety of infectious disease indications from the Institute for Protein Design at the University of Washington. Icosavax is located in Seattle.
Imbria Pharmaceuticals’ mission is to translate our understanding of cellular metabolism into innovative medicines that improve the lives of patients with limited or inadequate treatment options. The company was founded by doctors and launched by an all doctor executive team motivated by the promise of bringing new therapies to people in need. Imbria is propelled by a deep scientific interest in cellular metabolism and the mitochondria, and is guided by both values and a code of business conduct built upon their commitment to always put the patients, families and communities Imbria serves at the forefront of all that they do.
The company's technologies are engineered to activate the immune system's natural ability to create tumor-specific cytotoxic T cells to fight cancer and other chronic diseases. Immune Design's clinical programs are the product of its two synergistic discovery platforms: ZVex™ and GLAAS™. Immune Design has offices in Seattle, Washington and South San Francisco, California.
"We are very pleased that SV has decided to invest in Immune Design. Our companies share the vision of harnessing the immune system to discover and develop new immune-based therapies in a number of large human diseases in which both companies are interested."
Carlos Paya
President & CEO, Immune Design
Inozyme Pharma is a biotechnology company developing new medicines to treat rare disorders of calcification. These diseases are characterized by mineral imbalances, which lead to over calcification of soft tissues and under mineralization of bone. Founded in 2016 with technology licensed from Yale University, the company possesses a deep understanding of the biology of calcification which it is using to develop new medicines that have the potential to drastically improve the standard-of-care and change treatment paradigms. Inozyme’s lead candidate is an enzyme replacement therapy designed to treat calcification disorders of the circulatory system, bone and kidney for which insufficient treatment options currently exist.
Prior to its relaunch as Humanigen, Inc., KaloBios was a public biopharmaceutical company focused on the development of monoclonal antibody therapeutics to treat serious medical conditions with a primary clinical focus on severe respiratory diseases and cancer.
Kymera Therapeutics is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Powered by Pegasus™, a game-changing integrated degradation platform, Kymera is accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients.
Latigo is clinical stage company advancing a pipeline of Nav1.8 inhibiting small molecules for both acute and chronic pain.
LAVA Therapeutics is developing a proprietary bispecific antibody platform that engages gamma-delta T cells for the treatment of hematological and solid cancers. The company’s first-in-class immuno-oncology approach activates Vγ9Vδ2 T cells upon binding to membrane-expressed tumor targets. LAVA was founded in 2016 based on intellectual property originating from the Amsterdam University Medical Center. The company has established a highly experienced antibody research and development team located in Utrecht, the Netherlands (headquarters) and Philadelphia, USA.
Lumena Pharmaceuticals, acquired by Shire plc in June 2014, is a biopharmaceutical company dedicated to providing better treatment options for adults and children who suffer from rare and debilitating liver diseases and serious metabolic disorders. The company is focused on developing oral therapeutics to improve liver function, relieve disease symptoms and dramatically benefit patient health.
Lysosomal Therapeutics Inc. (LTI) is dedicated to innovative small molecule research and development in the field of neurodegeneration, yielding new treatment options for patients with severe neurological diseases. Our strategy leverages the clinically-validated link between lysosome-based genetic disorders and neurodegenerative diseases to establish a unique and effective molecular platform for novel drug discovery. LTI’s lead program targets Gaucher-related neurodegeneration, Parkinson’s disease and other synucleinopathies.
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody technology platforms, which it believes improve the performance of monoclonal antibodies and antibody-derived molecules. The company creates both differentiated molecules that are directed to novel cancer targets, as well as "bio-betters," which are drugs designed to improve upon marketed medicines. The combination of MacroGenics' technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies.
Matchpoint is a biotechnology company harnessing the power of covalency to discover precision covalent medicines to transform the treatment of immune diseases and other serious illnesses. The company's proprietary Advanced Covalent Exploration (ACE) platform integrates advanced chemoproteomics, machine learning and covalent chemistry library evolution. Matchpoint has an emerging pipeline of novel covalent medicines initially focused on immunology.
Medisafe is the largest medication management platform with over 7M registered users globally. Medisafe’s growth is rapidly accelerating as the healthcare industry turns to digital health solutions to support patients. • The Medisafe digital health platform delivers a next-generation patient engagement and medication adherence solution which leverages an AI data-driven personalization engine to improve health outcomes across a broad range of therapeutic areas with ecosystem integration and clinical validation.
Minervax is a clinical stage biotechnology company developing a prophylactic vaccine against Group B Streptococcus (GBS). Minervax’s protein only GBS vaccine targets maternal populations for the prevention of adverse pregnancy outcomes and life-threatening infections in newborns. The company was established in 2010 based on research from Lund University and is based in Copenhagen, Denmark.
Mirador is leveraging the latest advances in human genetics and cutting-edge data science to rapidly advance new precision medicines for patients living with chronic immune-mediated inflammatory and fibrotic diseases.
Muna Therapeutics discovers and develops therapies that slow or stop devastating neurodegenerative diseases including Alzheimer’s, Frontotemporal Dementia and Parkinson’s. These disorders impact memory, movement, language, behavior and personality resulting in disability and death of millions of patients around the globe. Muna focuses on identifying new medicines to preserve cognition and other brain functions and enhance resilience to neurodegenerative diseases.
Navitor is pioneering the selective targeting of mTORC1 activation to develop a new class of medicines for age-related diseases to improve human health. Navitor’s therapeutics are designed to selectively modulate the cellular signals that are aberrant in disease processes caused by the dysregulation of mTORC1 activation to address a wide range of diseases, including metabolic, neurodegenerative, autoimmune and musculoskeletal diseases, as well as age‐related immune suppression and several rare disorders. The company’s founding intellectual property is based on the groundbreaking discoveries related to the mTORC1 pathway and nutrient signaling mechanisms by Dr. David Sabatini at The Whitehead Institute for Biomedical Research.
NextPoint is advancing the field of immuno-oncology through its leading scientific work on HHLA2 biology; integrating foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors.
NodThera is a biotechnology company developing a new class of potent and selective NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation.
Normunity's initial drug discovery is focused on the challenge of immune cell exclusion, targeting mechanisms of trafficking to and infiltration into the tumor-- critical steps to turn a cold tumor hot. Normunity's therapies are immune normalizers that will be used as precision medicines for the treatment of cancer. By eliminating cancer’s defenses, immune normalizers free immune cells to carry out their expected work of recognizing and eliminating cancer.
Nucleai is committed to bringing the power of spatial biology to reality by providing pharmaceutical companies and clinicians with AI-powered image analysis applications. Nucleai's platform enhances drug development, supports treatment decisions and improves patient lives.
Nucleai's image analysis and biomarker discovery technology leverages real-world pathology, clinical and molecular datasets to better understand cancer biology, optimize patient stratification and improve patient care.
Nura Bio is a clinical-stage biopharmaceutical company developing neuroprotective therapies for the treatment of a broad range of neurological diseases. Nura Bio’s research and early development small molecule pipeline is focused on developing therapies that halt axon degeneration and/or modulate microglial responses to degeneration and injury, with the goal of conferring neuroprotection, across diseases of the central, peripheral, and ocular nervous systems.
Nuvig Therapeutics is a biotechnology company developing a recombinant, engineered Fc fragment (NVG-2089) that binds to type II Fc receptors and recapitulates the immunomodulatory effect of intravenous immunoglobulin (IVIg). NVG-2809 has the potential for a highly differentiated profile across a range of autoimmune indications. NVG-2089 has completed Phase 1 in healthy volunteers and is advancing into a proof-of-concept study in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
Odyssey Therapeutics is focused on discovering, developing, and commercializing the next generation of immunomodulators and oncology medicines. Composed of an expert team of drug hunters, scientists and industry leaders in foundational biology, chemistry and data sciences, Odyssey is transforming drug discovery to accelerate and drive the creation and efficient delivery of life-enhancing precision medicines to patients.
Omada Health is a digital behavioral medicine company that inspires and enables people to change the habits that put them most at risk for chronic conditions like heart disease and type 2 diabetes. The company is the largest CDC-recognized provider of the National Diabetes Prevention Program, and since its founding, has enrolled more than 100,000 participants. Omada’s program combines proven behavioral science, the power of professional health coaches and peer groups, connected technology, and world-class design to deliver clinically-meaningful results.
OMass Therapeutics is a biotechnology company discovering medicines against highly-validated target ecosystems, such as membrane proteins or intracellular complexes. The company’s unique OdyssION™ technology platform comprises novel biochemistry techniques, next-generation native mass spectrometry, and custom chemistry. This allows OMass to interrogate not just the target, but also the interaction of the target with its native ecosystem, separate from the confounding complexity of the cell. The result is cell-system fidelity with cell-free precision. OMass is advancing a pipeline of small molecule therapeutics in rare diseases and immunological conditions, therapeutics that target solute carriers, complex-bound proteins, and GPCRs.
Ovid Therapeutics Inc. is a public, New York based, biopharmaceutical company committed to transforming the lives of patients with rare and orphan diseases of the brain. Ovid focuses on patients and their unmet medical needs. Using the significant operational, product development and business development experience of its management team, Ovid aims to become a leading neurology company, with multiple products and a rich pipeline, coupled with compelling research and development.
Proteostasis Therapeutics, Inc. (PTI) is developing disease-modifying therapeutics for diseases of protein processing. Using the DRT™ platform, a phenotypic screening approach based on the use of functionally pertinent cellular assays and disease relevant models, PTI identifies highly selective drug candidates that modulate the proteostasis imbalance in the cell. PTI's lead program is focused on treating cystic fibrosis.
Q32 Bio, a biotechnology company developing biologics to restore healthy immune regulation.
QurAlis is a clinical-stage biotechnology company pioneering the path to conquering amyotrophic lateral sclerosis (ALS)and other neurodegenerative diseases through development of next-generation precision medicines to genetically validated targets. QurAlis is advancing a deep pipeline of antisense oligonucleotides (ASOs) and small molecule programs addressing sub-forms of ALS that account for the majority of ALS patients. The Company is also leveraging its proprietary platforms, unique biomarkers, and successes in ALS to expand QurAlis’ pipeline to other neurodegenerative diseases, such as frontotemporal dementia (FTD).
ReCode Therapeutics is an integrated genetic medicines company developing disease-modifying therapeutics using its powerful LNP delivery technology to target organs and tissues beyond the liver.
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.” With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier in biology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning. ROME is based in Cambridge, Mass.
Science 37 has created a new clinical trial operating model – the metasite™ – that unlocks access so researchers can find the right patients, and patients can find the right trials. Its Network Oriented Research Assistant, NORA™, is an accelerated patient-centric mobile research platform that connects everyone safely and securely. Science 37 offers end-to-end clinical trial services without geographic limitations, making clinical research faster to accelerate biomedical discovery. Ultimately, Science 37 enables better, faster, people-powered science and brings clinical trials to scale.
Selecta is developing immune modulating nanomedicines that enable novel biologic therapies by preventing harmful immune responses. Proprietary Synthetic Vaccine Particles (SVP) elicit lasting and antigen-specific tolerance to co-formulated biologic drugs. Selecta is conducting clinical studies to develop the first non-immunogenic biologic therapy to treat severe gout and is focused in the near-term on developing immunotherapeutic candidates that eliminate immune responses to adeno-associated virus (AAV) vectors that would enable a wide range of new applications for gene therapies.
"Sanofi has been a pioneer in recognizing the importance of antigen-specific immune modulation in vaccines, allergies, enzyme replacement therapy and auto-immune diseases. SV is of tremendous help to facilitate our dialogue within Sanofi and an esteemed member of our investor network."
Werner Cautreels, President & CEO, Selecta Biosciences
Sudo Biosciences is advancing a pipeline of programs targeting the tyrosine kinase 2 (TYK2) pseudokinase domain. TYK2 is a key mediator in cytokine signaling pathways that have been linked to a broad range of immune-mediated inflammatory conditions. The company’s pipeline of next generation TYK2 inhibitors includes a potential first- and best-in-class brain-penetrant candidate for the treatment of multiple sclerosis and neurodegenerative diseases with underlying neuroinflammation and a potential first- and best-in-class topical candidate for immune-mediated dermatologic diseases.
T-Therapeutics is a next-generation T cell receptor (TCR) company spun off from the University of Cambridge. The company was created to harness the power of T cell biology, evolved over millions of years, to create safe and effective treatments for many cancers and autoimmune diseases.
We combine world-leading expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration.
We are developing ‘optimal’ TCR based therapeutics using our proprietary OpTiMus® platform, based on a fully humanized TCR mouse that provides an almost unlimited source of unique, antigen-specific human TCRs. These TCRs are directed at multiple target classes, many of which have never been worked on before. We are developing a pipeline of first-in-class drugs that will become transformative medicines, reshaping the clinical landscape for patients with cancer or autoimmune diseases.
Therini Bio, Inc. is a vascular biology company focused on developing novel therapies based on a deep understanding of fibrin and its role in driving pathological inflammatory processes initiated by loss of vascular integrity. Our initial focus is on inflammation in neurodegenerative diseases, but the mechanism is implicated in a variety of peripheral indications. The Company was founded upon the pioneering work of Katerina Akassoglou, Ph.D., Senior Investigator at Gladstone Institutes and Professor of Neurology at the University of California, San Francisco. Dr. Akassoglou and colleagues discovered that fibrin, a blood-clotting factor, is implicated in the toxic inflammation that activates the brain’s immune cell response and damages neurons resulting in loss of brain function in models for Alzheimer’s disease and multiple sclerosis.
Tisento Therapeutics is a biotechnology company developing Zagociguat, a brain-penetrant sGC stimulator that is hypothesized to rebalance the dysregulated cellular pathways in MELAS and thus address a myriad of MELAS symptoms, including cognitive impairment and fatigue. Zagociguat demonstrated improvements across key domains of MELAS pathophysiology in a Phase 2a study and is currently in a Phase 2b study.
Ultragenyx is a public, clinical-stage biotechnology company committed to bringing to market life-transforming therapeutics for patients with rare and ultra-rare metabolic genetic diseases. Founded in 2010, the company is rapidly building a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no effective treatments.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
Unum Therapeutics uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body's own immune system to fight cancer. Unum's lead program, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, is in clinical testing to assess safety and efficacy.
"It's wonderful to have SV as a key part of the series A financing for Unum. Bernard and his team have established a strong track record of building great companies with the potential to really change the practice of medicine. Their strategic focus and knowledge of what Pharma values will be valuable assets for Unum"
Charles Wilson
President & CEO, Unum Therapeutics
Veralox Therapeutics Inc is developing first-in-class therapeutics targeting 12-Lipoxygenase (12-LOX) to bring new treatments to patients with rare blood disorders and diabetes. Through the 12-LOX pathway, Veralox’s approach targets a novel mechanism of the underlying disease pathologies. The company is advancing lead programs in heparin-induced thrombocytopenia (HIT), HIT with thrombosis (HITT) and type 1 diabetes (T1D). Veralox is committed and focused on developing better therapies to address these unmet medical needs.
Voluntis creates digital therapeutics that empower people suffering from chronic conditions to self-manage their treatment every day, thus improving real-world outcomes. Combining mobile and web apps, Voluntis’ solutions deliver personalized recommendations to the patient and the care team so that they can, for example, adjust treatment dosage, manage side effects or monitor symptoms. Its digital therapeutics include Insulia® and Diabeo® in diabetes in partnership with Sanofi and Onduo, as well as eCO, with AstraZeneca, and ZEMY, with Roche, in oncology.
"We are delighted to extend our long-standing business partnership with Sanofi through the participation of Sanofi Ventures in our IPO. This investment will help support our ambitious growth strategy with regards to our digital therapeutics portfolio in diabetes and oncology."
Pierre Leurent
CEO and co-founder, VOLUNTIS
Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Formed in 2014 by renowned biotech industry leader, Tony Coles, M.D., and protein folding science pioneer, Susan Lindquist, Ph.D., the company is initially focused on discovering disease-modifying therapies for patients with Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS). Leveraging its three integrated platforms, Yumanity’s innovative new approach to drug discovery and development concentrates on reversing the cellular phenotypes and disease pathologies caused by protein misfolding.
